Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 11/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 9/20 | 0.40 |
| ▸ | DPP4 | P27487 | 6/20 | 0.40 |
| ▸ | CA1 | P00915 | 4/20 | 0.40 |
| ▸ | CA2 | P00918 | 4/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 9/20 | 0.39 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.38 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7214635 | 0.82 | CNR2 (0.53) | DNM1DPP7DPP9DPP4CA1 | |
| SCHEMBL12415206 | 0.80 | ASAH1 (0.44) | DPP7CA1CA2PLA2G2CMEN1 | |
| SCHEMBL23634768 | 0.80 | TAS1R3 (0.46) | DNM1DPP7DPP9DPP4CA1 | |
| SCHEMBL12415207 | 0.77 | PLA2G2C (0.36) | DPP7DPP9DPP4CA1CA2 | |
| SCHEMBL7176522 | 0.77 | NOD1 (0.58) | CA2 | |
| SCHEMBL7176520 | 0.77 | NOD1 (0.58) | CA2 | |
| SCHEMBL1701005 | 0.77 | CA2 (0.45) | CA1CA2PLA2G2CMAPK1 | |
| SCHEMBL906579 | 0.77 | DNM1 (0.58) | DNM1PLA2G2CMEN1KMT2AFAAH | |
| SCHEMBL8624514 | 0.76 | MEN1 (0.56) | DNM1PLA2G2CMEN1KMT2AFAAH | |
| SCHEMBL10745240 | 0.75 | NOD1 (0.61) | KMT2AFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110195025-A1 | ANIONIC OLIGOSACCHARIDE CONJUGATES | GLYCAN BIOSCIENCES PTY LTD (AU) | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195025-A1 | ANIONIC OLIGOSACCHARIDE CONJUGATES | FUT6, FUT5, CSGALNACT1 | DNM1 2321/4885DPP7 230/4885DPP9 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.